natgillin/translations-raw huggingface dataset:
Included in the injection kit: a One vial containing the powder b One pre-filled syringe containing the solvent c One vial adapter for medicinal product reconstitution d One safety injection needle (20G x 1.5″)
Uključeno u set za primjenu injekcije: a Jedna bočica koja sadrži prašak b Jedna napunjena štrcaljka koja sadrži otapalo c Jedan nastavak za bočicu za rekonstituciju lijeka d Jedna igla (20G x 1,5″) za injekciju, sa zaštitnim mehanizmom
Solvent for Signifor
Otapalo za Signifor
Liver tests
Testovi funkcije jetre
Transient elevations in liver enzymes have been reported with the use of somatostatin analogues and were also observed in patients receiving pasireotide in clinical studies.
Kod uporabe analoga somatostatina bila su prijavljena prolazna povišenja jetrenih enzima koja su također bila uočena u bolesnika koji su primali pasireotid u kliničkim ispitivanjima.
The development of hyperglycaemia appears to be related to decreases in secretion of insulin and of incretin hormones (i.e. glucagon-like peptide-1 [GLP-1] and glucose-dependent insulinotropic polypeptide [GIP]).
Razvoj hiperglikemije je čini se povezan sa smanjenjima u izlučivanju inzulina i inkretinskih hormona (tj. glukagonu sličnog peptida-1 [engl. glucagon-like peptide-1, GLP-1] i inzulinotropnog polipeptida ovisnog o glukozi ([engl. glucose-dependent insulinotropic polypeptide, GIP]).
Step 1:
Korak 1:
Step 8:
Korak 8:
Powder: poly(D,L-lactide-co-glycolide) (50-60:40-50), poly(D,L-lactide-co-glycolide) (50:50).
Prašak: poli(D,L-laktid-ko-glikolid) (50-60:40-50), poli(D,L-laktid-ko-glikolid) (50:50).
In the acromegaly study C2305, the proportion of patients with newly occurring notable QT/QTc intervals was comparable between pasireotide intramuscular use and octreotide intramuscular use groups up to crossover, with few notable outlying values.
U ispitivanju u bolesnika s akromegalijom C2305 udio bolesnika s novonastalim zamjetnim QT/QTc intervalima bio je usporediv između skupina koje su primale pasireotid primijenjen intramuskularno i onih koje su primale oktreotid primijenjen intramuskularno sve do ukrižene zamjene ispitivanog lijeka, uz vrlo malo zamjetnih stršećih vrijednosti.
Female patients of childbearing potential should be advised to use adequate contraception if necessary during treatment with Signifor (see section 4.6).
Bolesnice reproduktivne dobi potrebno je upozoriti da tijekom liječenja Signiforom, ako je potrebno, koriste djelotvornu kontracepciju (vidjeti dio 4.6).
Glucose metabolism disorders
Poremećaji metabolizma glukoze
Screw the safety injection needle onto the syringe.
Zavrtanjem pričvrstite iglu za injekciju sa zaštitnim mehanizmom na štrcaljku.
Month 12 * Includes one patient with significant outlying results who had a percent change from baseline of
* Uključuje jednog bolesnika sa značajnim izraženim rezultatima koji je imao postotak promjene od početne vrijednosti od +542,2%.
Poly(D,L-lactide-co-glycolide) (50-60:40-50) Poly(D,L-lactide-co-glycolide) (50:50)
Poli(D,L-laktid-ko-glikolid) (50-60:40-50) Poli(D,L-laktid-ko-glikolid) (50:50)
pimozide, haloperidol, tiapride, amisulpride, sertindole, methadone); - medicines to treat hay fever and other allergies (terfenadine, astemizole, mizolastine); - medicines used in the prevention or treatment of malaria (chloroquine, halofantrine,
pimozid, haloperidol, tiaprid, amisulpirid, sertindol, metadon); - lijekove koji liječe peludnu groznicu i druge alergije (terfenadin, astemizol, mizolastin); - lijekove koji se koriste u sprečavanju ili liječenju malarije (klorokin, halofantrin, lumefantrin); - lijekove za kontroliranje krvnog tlaka, kao što su:
- In the solvent: carmellose sodium, mannitol, poloxamer 188, water for injections.
U otapalu: karmelozanatrij, manitol, poloksamer 188, voda za injekcije.
a One vial containing the powder b One pre-filled syringe containing the solvent c One vial adapter for medicinal product reconstitution d One safety injection needle (20G x 1.5″)
a Jedna bočica koja sadrži prašak b Jedna napunjena štrcaljka koja sadrži otapalo c Jedan nastavak za bočicu za rekonstituciju lijeka d Jedna igla (20G x 1,5″) za injekciju, sa zaštitnim mehanizmom
One-point-cut colourless, type I glass ampoule containing 1 ml of solution.
Bezbojna staklena ampula (staklo tipa I) sa zarezom na mjestu loma koja sadrži 1 ml otopine.
Studies in rats in which pasireotide was administered via the subcutaneous route have shown effects on female reproductive parameters (see section 5.3).
Ispitivanja na štakorima u kojih se pasireotid primjenjivao supkutano pokazala su učinke na ženske reproduktivne parametre (vidjeti dio 5.3).
In healthy volunteers, pasireotide is rapidly absorbed and peak plasma concentration is reached within 0.25-0.5 h. Cmax and AUC are approximately dose-proportional following administration of single and multiple doses.
U zdravih dobrovoljaca pasireotid se brzo apsorbira, a vršna koncentracija u plazmi postiže se u roku od 0,25-0,5 h.
Powder and solvent for suspension for injection
Prašak i otapalo za suspenziju za injekciju
For information on the instructions for use, please see the end of the package leaflet “How to inject Signifor”.
Za informacije o uputama za uporabu, molimo vidjeti kraj upute o lijeku
Diarrhoea, abdominal pain, nausea
Proljev, bol u abdomenu, mučnina
The influence of the P-gp inhibitor verapamil on the pharmacokinetics of subcutaneous pasireotide was tested in a drug-drug interaction study in healthy volunteers.
U ispitivanju interakcija među lijekovima u zdravih dobrovoljaca ispitivan je utjecaj P-gp inhibitora verapamila na farmakokinetiku supkutano primijenjenog pasireotida.
PRE-FILLED SYRINGE LABEL
NALJEPNICA ZA NAPUNJENU ŠTRCALJKU
No clinical studies in subjects with liver impairment have been performed with pasireotide intramuscular use.
Nisu provedena klinička ispitivanja s pasireotidom primijenjenim intramuskularno u ispitanika s oštećenjem jetre.
GH<2.5 μg/l * Primary endpoint (patients with IGF-1< lower limit of normal (LLN) were not considered “responders”).
* Mjera primarnog ishoda (bolesnici s IGF-1 ispod donje granice normale (DGN) nisu se smatrali bolesnicima s odgovorom).
INSTRUCTIONS FOR USE OF SIGNIFOR POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION
UPUTE ZA PRIMJENU SIGNIFOR PRAŠKA I OTAPALA ZA SUSPENZIJU ZA INJEKCIJU
What Signifor looks like and contents of the pack Signifor solution for injection is a clear, colourless solution in an ampoule.
Signifor otopina za injekciju je bistra, bezbojna otopina u ampuli.
Studies in animals in which pasireotide was administered via the subcutaneous route have shown reproductive toxicity (see section 5.3).
Ispitivanja na životinjama u kojima se pasireotid primjenjivao supkutano pokazala su reproduktivnu toksičnost (vidjeti dio 5.3).
In acromegaly patients, gastrointestinal disorders were less frequent in inadequately controlled patients compared to medically naïve patients.
U bolesnika s akromegalijom poremećaji probavnog sustava bili su manje učestali u neodgovarajuće kontroliranih bolesnika u usporedbi s bolesnicima koji nisu ranije primali terapiju lijekovima.
Glycosylated haemoglobin increased
Povišenje glikiranog hemoglobina
How to use Signifor
Kako primjenjivati Signifor
In Cushing's disease patients, elevated FPG levels was the most frequently reported CTC Grade 3 laboratory abnormality (14.7% of patients) in the phase III study G2304; with no cases of Grade 4 reported.
U bolesnika s Cushingovom bolešću povišene razine FPG-a bile su najčešće prijavljene laboratorijske abnormalnosti CTC stupnja 3 (14,7% bolesnika) u ispitivanju G2304 faze III; nije bilo prijavljenih slučajeva stupnja 4. Srednja povećanja HbA1c bila su manje izražena u bolesnika s normalnom glikemijom kod uključenja u ispitivanje u usporedbi s pred-dijabetičkim ili dijabetičkim bolesnicima.
In a human ADME study 55.9±6.63% of the radioactive pasireotide subcutaneous dose was recovered over the first 10 days after administration, including 48.3±8.16% of the radioactivity in faeces and 7.63±2.03% in urine.
U ADME (apsorpcija, distribucija, metabolizam i eliminacija) ispitivanju u ljudi 55,9±6,63% radioaktivne doze supkutanog pasireotida bilo je detektirano tijekom prvih 10 dana nakon primjene, uključujući 48,3±8,16% radioaktivnosti u stolici i 7,63±2,03% u mokraći.
Tartaric acid Sodium hydroxide Water for injections
6.1 Popis pomoćnih tvari manitol tartaratna kiselina natrijev hidroksid voda za injekcije
You may experience yellowing of the skin, dark urine,
Možete primijetiti žutilo kože, tamnu mokraću, blijede stolice i svrbež.
- Gallstones.
- Žučni kamenci.
Adverse reactions of hyperglycaemia and diabetes mellitus led to study discontinuation in 3 (2.0%) and 4 patients (2.7%), respectively.
Hiperglikemija kao nuspojava dovela je do prekida ispitivanja u 3 (2,0%) bolesnika, a šećerna bolest u 4 (2,7%) bolesnika.
Signifor 0.3 mg solution for injection Signifor 0.6 mg solution for injection Signifor 0.9 mg solution for injection
Signifor 0,3 mg otopina za injekciju Signifor 0,6 mg otopina za injekciju Signifor 0,9 mg otopina za injekciju
In a human ADME study 55.9±6.63% of the radioactive dose was recovered over the first 10 days after administration, including 48.3±8.16% of the radioactivity in faeces and 7.63±2.03% in urine.
U ADME (apsorpcija, distribucija, metabolizam i eliminacija) ispitivanju u ljudi 55,9±6,63% radioaktivne doze bilo je detektirano tijekom prvih 10 dana nakon primjene, uključujući 48,3±8,16% radioaktivnosti u stolici i 7,63±2,03% u mokraći.
Slowly push the plunger all the way down to transfer all the solvent in the vial.
Polako gurnite klip do kraja kako biste prenijeli cjelokupno otapalo u bočicu.
Available data in rats in which pasireotide was administered via the subcutaneous route have shown excretion of pasireotide in milk (see section 5.3).
Dostupni podaci u štakora u kojih se pasireotid primjenjivao supkutano pokazuju da se pasireotid izlučuje u mlijeko (vidjeti dio 5.3).
If you have any questions, contact your doctor, nurse or pharmacist.
Ako imate ikakvih pitanja, obratite se svom liječniku, medicinskoj sestri ili ljekarniku.
Signifor 20 mg: each vial contains 20 mg pasireotide (as pasireotide pamoate).
Signifor 20 mg: svaka bočica sadrži 20 mg pasireotida (u obliku pasireotidpamoata).
- The other ingredients are: - In the powder: poly(D,L-lactide-co-glycolide) (50-60:40-50),
- Drugi sastojci su: U prašku: poli(D,L-laktid-ko-glikolid) (50-60:40-50), poli(D,L-laktid-ko-glikolid)
Treatment of adult patients with Cushing's disease for whom surgery is not an option or for whom surgery has failed.
Liječenje odraslih bolesnika s Cushingovom bolešću kod kojih kirurški zahvat nije moguć ili kod kojih kirurški zahvat nije uspio.
Step 9:
Korak 9:
AMPOULE LABEL
NALJEPNICA ZA AMPULU
Signifor 0.9 mg solution for injection EU/1/12/753/009-0012
Signifor 0,9 mg otopina za injekciju EU/1/12/753/009-0012
It is also used to treat Cushing's disease in adult patients for whom surgery is not an option or for whom surgery has failed.
Primjenjuje se i za liječenje Cushingove bolesti u odraslih bolesnika kod kojih kirurški zahvat nije moguć ili kod kojih kirurški zahvat nije uspio.
Remove the cover from the needle.
Skinite zaštitni poklopac s igle.
Mild transient elevations in aminotransferases are commonly observed in patients treated with pasireotide.
U bolesnika liječenih pasireotidom često se opažaju blaga prolazna povišenja aminotransferaza.
Signifor 0.3 mg solution for injection Signifor 0.6 mg solution for injection Signifor 0.9 mg solution for injection pasireotide
Signifor 0,3 mg otopina za injekciju Signifor 0,6 mg otopina za injekciju Signifor 0,9 mg otopina za injekciju pasireotid
1 pre-filled syringe with 2 ml solvent 1 safety-engineered needle 1 vial adapter
1 napunjena štrcaljka s 2 ml otapala 1 igla sa zaštitnim mehanizmom 1 nastavak za bočicu
Signifor 0.6 mg solution for injection EU/1/12/753/005-008
Signifor 0,6 mg otopina za injekciju EU/1/12/753/005-008
Remove the cap from the syringe pre-filled with solvent and screw the syringe onto the vial adapter.
Uklonite zatvarač sa štrcaljke napunjene otapalom i zavrtanjem pričvrstite štrcaljku na nastavak za bočicu.
Signifor is intended for intramuscular use.
Signifor je namijenjen za primjenu u mišić.
Hyperglycaemia and, less frequently, hypoglycaemia, were observed in subjects participating in clinical studies with pasireotide (see section 4.8).
U ispitanika koji su sudjelovali u kliničkim ispitivanjima s pasireotidom bile su opažene hiperglikemija i, manje učestalo, hipoglikemija (vidjeti dio 4.8).
How to store Signifor
Kako čuvati Signifor
Vomiting, abdominal pain upper
Povraćanje, bol u gornjem dijelu abdomena
It is used to treat Cushing's disease in adult patients for whom surgery is not an option or for whom surgery has failed.
Primjenjuje se za liječenje Cushingove bolesti u odraslih bolesnika kod kojih kirurški zahvat nije moguć ili kod kojih kirurški zahvat nije uspio.
Multipack: 3 packs of 1 injection kit
Prašak i otapalo za suspenziju za injekciju Višestruko pakiranje: 3 pakiranja s po 1 setom za primjenu injekcije
increased appetite with weight loss, tiredness.
Možete osjetiti pretjeranu žeđ, povećano mokrenje, povećani apetit uz gubitak težine, umor.
Signifor 60 mg powder and solvent for suspension for injection EU/1/12/753/016-017
Signifor 60 mg prašak i otapalo za suspenziju za injekciju EU/1/12/753/016-017
Within each system organ class, adverse reactions are ranked by frequency.
Unutar svakog organskog sustava nuspojave su razvrstane po učestalosti.
Signifor 20 mg powder and solvent for suspension for injection One vial contains 20 mg pasireotide (as pasireotide pamoate).
Signifor 20 mg prašak i otapalo za suspenziju za injekciju Jedna bočica sadrži 20 mg pasireotida (u obliku pasireotidpamoata).
Signifor 0.3 mg solution for injection EU/1/12/753/001-004
Signifor 0,3 mg otopina za injekciju EU/1/12/753/001-004
procainamide, quinidine, sotalol, dofetilide, ibutilide, amiodarone or dronedarone; - medicines to treat bacterial infections (by mouth: clarithromycin, moxifloxacin; via injection:
prokainamid, kinidin, sotalol, dofetilid, ibutilid, amiodaron ili dronedaron; - lijekove koji liječe bakterijske infekcije (kroz usta: klaritromicin, moksifloksacin; putem injekcije: eritromicin, pentamidin); - lijekove koji liječe gljivične infekcije (ketokonazol, osim u šamponu); - lijekove koji liječe određene psihijatrijske poremećaje (klorpromazin, tioridazin, flufenazin,
Signifor 60 mg: each vial contains 60 mg pasireotide (as pasireotide pamoate).
Signifor 60 mg: svaka bočica sadrži 60 mg pasireotida (u obliku pasireotidpamoata).
Asymptomatic elevations in lipase and amylase were observed in patients receiving pasireotide in clinical studies.
U bolesnika koji su primali pasireotid u kliničkim ispitivanjima bila su uočena asimptomatska povišenja lipaze i amilaze.
Signifor 30 mg: each vial contains 30 mg pasireotide (as pasireotide pamoate).
Signifor 30 mg: svaka bočica sadrži 30 mg pasireotida (u obliku pasireotidpamoata).
Compound hsst1
Spoj hsst1
Signifor 20 mg is available in unit packs containing one vial of powder with 20 mg pasireotide and one pre-filled syringe with 2 ml solvent.
Signifor 20 mg dostupan je u jediničnim pakiranjima koja sadrže jednu bočicu praška s 20 mg pasireotida i jednu napunjenu štrcaljku s 2 ml otapala.
Signifor 10 mg: each vial contains 10 mg pasireotide (as pasireotide pamoate).
Signifor 10 mg: svaka bočica sadrži 10 mg pasireotida (u obliku pasireotidpamoata).
- medicines to treat certain psychiatric disorders (chlorpromazine, thioridazine, fluphenazine, pimozide, haloperidol, tiapride, amisulpride, sertindole, methadone); - medicines to treat hay fever and other allergies (terfenadine, astemizole, mizolastine); - medicines used in the prevention or treatment of malaria (chloroquine, halofantrine, lumefantrine); - medicines to control blood pressure such as:
- lijekove koji liječe nepravilne otkucaje srca, kao što su lijekovi koji sadrže dizopiramid, prokainamid, kinidin, sotalol, dofetilid, ibutilid, amiodaron ili dronedaron; - lijekove koji liječe bakterijske infekcije (kroz usta: klaritromicin, moksifloksacin; putem injekcije: eritromicin, pentamidin); - lijekove koji liječe gljivične infekcije (ketokonazol, osim u šamponu); - lijekove koji liječe određene psihijatrijske poremećaje (klorpromazin, tioridazin, flufenazin, pimozid, haloperidol, tiaprid, amisulpirid, sertindol, metadon); - lijekove koji liječe peludnu groznicu i druge alergije (terfenadin, astemizol, mizolastin); - lijekove koji se koriste u sprečavanju ili liječenju malarije (klorokin, halofantrin, lumefantrin); - lijekove za kontroliranje krvnog tlaka, kao što su:
One vial contains 20 mg pasireotide (as pasireotide pamoate).
Jedna bočica sadrži 20 mg pasireotida (u obliku pasireotidpamoata).
Signifor 40 mg: each vial contains 40 mg pasireotide (as pasireotide pamoate).
Signifor 40 mg: svaka bočica sadrži 40 mg pasireotida (u obliku pasireotidpamoata).
Signifor 60 mg powder and solvent for suspension for injection One vial contains 60 mg pasireotide (as pasireotide pamoate).
Signifor 60 mg prašak i otapalo za suspenziju za injekciju Jedna bočica sadrži 60 mg pasireotida (u obliku pasireotidpamoata).
Signifor 40 mg powder and solvent for suspension for injection EU/1/12/753/014-015
Signifor 40 mg prašak i otapalo za suspenziju za injekciju EU/1/12/753/014-015
Signifor 0.9 mg: One ampoule of 1 ml solution contains 0.9 mg pasireotide (as pasireotide diaspartate).
Signifor 0,9 mg: Jedna ampula s 1 ml otopine sadrži 0,9 mg pasireotida (u obliku pasireotiddiaspartata).
One vial contains 60 mg pasireotide (as pasireotide pamoate).
Jedna bočica sadrži 60 mg pasireotida (u obliku pasireotidpamoata).
Pasireotide
Doziranje
Signifor 10 mg is available in unit packs containing one vial of powder with 10 mg pasireotide and one pre filled syringe with 2 ml solvent.
Signifor 10 mg dostupan je u jediničnim pakiranjima koja sadrže jednu bočicu praška s 10 mg pasireotida i jednu napunjenu štrcaljku s 2 ml otapala.
1 ml solution for injection contains 0.9 mg pasireotide (as pasireotide diaspartate).
1 ml otopine za injekciju sadrži 0,9 mg pasireotida (u obliku pasireotiddiaspartata).
Signifor 40 mg powder and solvent for suspension for injection One vial contains 40 mg pasireotide (as pasireotide pamoate).
Signifor 40 mg prašak i otapalo za suspenziju za injekciju Jedna bočica sadrži 40 mg pasireotida (u obliku pasireotidpamoata).
Signifor 10 mg powder and solvent for suspension for injection One vial contains 10 mg pasireotide (as pasireotide pamoate).
Signifor 10 mg prašak i otapalo za suspenziju za injekciju Jedna bočica sadrži 10 mg pasireotida (u obliku pasireotidpamoata).
Signifor 10 mg powder and solvent for suspension for injection EU/1/12/753/018
Signifor 10 mg prašak i otapalo za suspenziju za injekciju EU/1/12/753/018
Signifor 0.6 mg: One ampoule of 1 ml solution contains 0.6 mg pasireotide (as pasireotide diaspartate).
Signifor 0,6 mg: Jedna ampula s 1 ml otopine sadrži 0,6 mg pasireotida (u obliku pasireotiddiaspartata).
Signifor 30 mg is available in unit packs containing one vial of powder with 30 mg pasireotide and one pre filled syringe with 2 ml solvent.
Signifor 30 mg dostupan je u jediničnim pakiranjima koja sadrže jednu bočicu praška s 30 mg pasireotida i jednu napunjenu štrcaljku s 2 ml otapala.
Signifor 30 mg powder and solvent for suspension for injection One vial contains 30 mg pasireotide (as pasireotide pamoate).
Signifor 30 mg prašak i otapalo za suspenziju za injekciju Jedna bočica sadrži 30 mg pasireotida (u obliku pasireotidpamoata).
Signifor 60 mg is available in unit packs containing one vial of powder with 60 mg pasireotide and one pre-filled syringe with 2 ml solvent.
Signifor 60 mg dostupan je u jediničnim pakiranjima koja sadrže jednu bočicu praška s 60 mg pasireotida i jednu napunjenu štrcaljku s 2 ml otapala.
1 ml solution for injection contains 0.6 mg pasireotide (as pasireotide diaspartate).
1 ml otopine za injekciju sadrži 0,6 mg pasireotida (u obliku pasireotiddiaspartata).
Signifor 40 mg is available in unit packs containing one vial of powder with 40 mg pasireotide and one pre-filled syringe with 2 ml solvent.
Signifor 40 mg je dostupan u jediničnim pakiranjima koja sadrže jednu bočicu praška s 40 mg pasireotida i jednu napunjenu štrcaljku s 2 ml otapala.
congestive heart failure, unstable angina or clinically significant bradycardia.
- s nekontroliranom ili značajnom bolesti srca, kongestivnim zatajenjem srca, nestabilnom anginom ili klinički značajnom bradikardijom. - koji uzimaju antiaritmike ili druge tvari za koje se zna da dovode do produženja QT intervala
Signifor 0.9 mg injection pasireotide
Signifor 0,9 mg otopina za injekciju pasireotid
One vial contains 10 mg pasireotide (as pasireotide pamoate).
Jedna bočica sadrži 10 mg pasireotida (u obliku pasireotidpamoata).
One vial contains 30 mg pasireotide (as pasireotide pamoate).
Jedna bočica sadrži 30 mg pasireotida (u obliku pasireotidpamoata).
Signifor 20 mg powder and solvent for suspension for injection EU/1/12/753/013
Signifor 20 mg prašak i otapalo za suspenziju za injekciju EU/1/12/753/013
“prolongation of the QT interval”, or “QT prolongation”; - low levels of potassium or magnesium in your blood; - gallstones; - or if you are taking anticoagulants (medicines used to reduce the clotting ability of the blood),
(obično se osjeća kao pritisak, težina, stezanje, stiskanje ili bol u grudnom košu), - poremećaj srčanog ritma, kao što su nepravilni otkucaji srca ili abnormalni električni signal koji se zove “produženje QT intervala”, ili “QT produženje”, - niske razine kalija ili magnezija u krvi, - žučne kamence, - ili ako uzimate antikoagulanse (lijekove koji se koriste za smanjivanje sposobnosti zgrušavanja krvi), liječnik će Vam pratiti parametre koagulacije i možda prilagoditi dozu antikoagulansa.
Signifor 0.6 mg injection pasireotide
Signifor 0,6 mg otopina za injekciju pasireotid
Signifor 0.3 mg: One ampoule of 1 ml solution contains 0.3 mg pasireotide (as pasireotide diaspartate).
Signifor 0,3 mg: Jedna ampula s 1 ml otopine sadrži 0,3 mg pasireotida (u obliku pasireotiddiaspartata).
Injection site reaction, fatigue
Reakcije na mjestu primjene, umor
Injection sites angle
Mjesta primjene kut od
One vial contains 40 mg pasireotide (as pasireotide pamoate).
Jedna bočica sadrži 40 mg pasireotida (u obliku pasireotidpamoata).
Signifor 0.3 mg injection pasireotide
Signifor 0,3 mg otopina za injekciju pasireotid
Signifor 30 mg powder and solvent for suspension for injection EU/1/12/753/019
Signifor 30 mg prašak i otapalo za suspenziju za injekciju EU/1/12/753/019
Switch from subcutaneous to intramuscular formulation in Cushing's disease There are no clinical data available on switching from the subcutaneous to the intramuscular pasireotide formulation.
Ne postoje dostupni klinički podaci o prelasku sa supkutane na intramuskularnu formulaciju pasireotida.
Signifor 20 mg powder and solvent for suspension for injection pasireotide
Signifor 20 mg prašak i otapalo za suspenziju za injekciju pasireotid
1 ml solution for injection contains 0.3 mg pasireotide (as pasireotide diaspartate).
1 ml otopine za injekciju sadrži 0,3 mg pasireotida (u obliku pasireotiddiaspartata).
Signifor 60 mg powder and solvent for suspension for injection pasireotide
Signifor 60 mg prašak i otapalo za suspenziju za injekciju pasireotid
Signifor 10 mg powder and solvent for suspension for injection pasireotide
Signifor 10 mg prašak i otapalo za suspenziju za injekciju pasireotid
Month 6
Dublin 4
Signifor 40 mg powder and solvent for suspension for injection pasireotide
Signifor 40 mg prašak i otapalo za suspenziju za injekciju pasireotid
Signifor 30 mg powder and solvent for suspension for injection pasireotide
Signifor 30 mg prašak i otapalo za suspenziju za injekciju pasireotid
Signifor 20 mg powder for injection pasireotide
Signifor 20 mg prašak za injekciju pasireotid i.m.
Signifor 10 mg powder for injection pasireotide
Signifor 10 mg prašak za injekciju pasireotid i.m.
Signifor 30 mg powder for injection pasireotide
Signifor 30 mg prašak za injekciju pasireotid i.m.
Common
Physical
Signifor 40 mg powder for injection pasireotide
Signifor 40 mg prašak za injekciju pasireotid i.m.